Table. Patient Demographics, Treatment, and Clinical Characteristics at the End of Chemoradiotherapy (Main Exploratory Analyses).
| Characteristic | Patients, No. (%) | |
|---|---|---|
| Durvalumab group (n = 299) | Nondurvalumab group (n = 77) | |
| Age, median (IQR), y | 67.0 (60.0-74.0) | 70.0 (64.0-74.0) |
| Age ≥65 y | 184 (61.5) | 56 (72.7) |
| Sex | ||
| Male | 167 (55.9) | 46 (59.7) |
| Female | 132 (44.1) | 31 (40.3) |
| Race | ||
| Asian | 6 (2.1) | 2 (2.9) |
| Black or African American | 23 (8.1) | 8 (11.4) |
| White | 228 (80.6) | 51 (72.9) |
| Othera | 26 (9.2) | 9 (12.9) |
| Missingb | 16 | 7 |
| Smoking history | ||
| Yes | 284 (95.0) | 73 (94.8) |
| No | 15 (5.0) | 4 (5.2) |
| ECOG performance statusc | ||
| 0-1 | 214 (89.2) | 38 (82.6) |
| >1 | 26 (10.8) | 8 (17.4) |
| Missingb | 59 | 31 |
| AJCC disease stage at initial diagnosisd | ||
| IIIA | 173 (57.9) | 56 (72.7) |
| IIIB | 116 (38.8) | 20 (26.0) |
| IIIC | 10 (3.3) | 1 (1.3) |
| Histology | ||
| Squamous | 147 (50.9) | 35 (47.9) |
| Nonsquamous | 142 (49.1) | 38 (52.1) |
| Missingb | 10 | 4 |
| PD-L1 tumor cell expressione | ||
| ≥1% | 35 (66.0) | 8 (66.7) |
| <1% | 18 (34.0) | 4 (33.3) |
| Missingb | 246 | 65 |
| EGFR variant statuse | ||
| Negative | 54 (94.7) | 14 (100) |
| Positive | 3 (5.3) | 0 |
| Missing/unknown/indeterminateb | 242 | 63 |
| Region | ||
| South | 134 (47.3) | 42 (59.2) |
| Midwest | 70 (24.7) | 11 (15.5) |
| Northeast | 44 (15.5) | 11 (15.5) |
| West | 35 (12.4) | 7 (9.9) |
| Missingb | 16 | 6 |
| Prior platinum agent | ||
| Any cisplatin | 45 (15.1) | 8 (10.4) |
| Carboplatin only | 254 (84.9) | 69 (89.6) |
Abbreviations: AJCC, American Joint Committee on Cancer; ECOG, Eastern Cooperative Oncology Group; PD-L1, programmed cell death-ligand 1.
The groups included in other race are not specified in the database.
Missing values were not imputed; all reported percentages were calculated using the number of patients with available data as the denominator.
Between the chemoradiotherapy (CRT) end date and 42 days after the CRT end date, inclusive.
Based on the date range that patients were diagnosed in this study, they may have been diagnosed according to either the 7th or 8th editions of the AJCC Cancer Staging Manual.
No PD-L1 or EGFR data were available within 4 weeks before or after the end of CRT, so this is, instead, within 4 weeks before or after the date of the start of CRT. If multiple records were available, the record closest to the CRT start date is reported. If a patient had values both before and after the CRT start date of the same duration of time from that date, then the value before the date was analyzed.